Digital Pathology Clearance Accelerates U.S. Market Entry
PathPresenter wins FDA clearance for digital pathology viewer, advancing primary diagnosis and LIS integration.
Shajini
TISSIUM’s De Novo FDA Authorization Signals Industry Shift
FDA De Novo nod for TISSIUM’s COAPTIUM CONNECT: a new era in sutureless nerve repair.
Revolution Medicines Secures Powerhouse $2B Funding in Groundbreaking Royalty Pharma Deal
Revolution inks $2B flexible deal with Royalty Pharma to fund RAS(ON) inhibitors in cancer.
Arialys Therapeutics Targets First in Class Precision Therapy for Autoimmune Encephalitis
ART5803 targets NMDA receptor autoantibodies, advancing precision therapy for autoimmune encephalitis.
Strategic Industry Context: Alzheimer’s Drug Reimbursement Faces Global Pressure
NICE deems donanemab and lecanemab not cost-effective, blocks NHS coverage for Alzheimer’s drugs.
ENHERTU Advances First-Line Endometrial Therapy in Phase 3 Trial
ENHERTU Phase 3 trial launches for first-line endometrial therapy targeting HER2-expressing tumors.
Alexion Strikes Bold AI Partnership for Rare Disease Detection
AI partnership targets rare bone disease affecting 1 in 6,000 patients.
ZEISS CLARUS 700 Gains China NMPA Approval for Retinal Imaging
ZEISS expands retinal diagnostic capabilities in China with CLARUS 700 ultra-widefield imaging system approval.
GoodRx Disrupts Pharmacy Economics with Cost-Plus Pricing
GoodRx reshapes independent pharmacy economics through transparent cost-plus pricing model launch.
Medacta Showcases Advanced Orthopedic Solutions at ISAKOS
Medacta highlights cutting-edge orthopedic innovations at ISAKOS 2024.